A novel dairy-derived isolate that inhibits adipogenesis and significantly reduces weight gain in a high fat animal model

A novel, highly enriched bioactive bovine whey protein fraction (LAP001) was shown to directly inhibit adipocyte differentiation and lipid accumulation over a wide concentration range. Further in vitro characterisation showed that LAP001 suppressed induction of PPARγ expression in a dose-dependent manner. Administration of LAP001 to rats maintained on a high-fat diet over a 28-day period led to a significant reduction in weight gain and prevented a rise in plasma glucose concentration without significantly affecting plasma insulin concentrations. In additional, there was a beneficial modulation of major serum adipokines (decreased leptin and increased adiponectin concentration) that impact on metabolic parameters related to obesity. As such, LAP001 represents a novel and potentially attractive dairy-derived fraction for further development and testing as an agent that can inhibit weight gain, and aid in the control of obesity-related metabolic disorders.